Table 1 Regression analysis of baseline log2 transformed periostin with baseline characteristics in COPD-patients, healthy smokers and never-smokers
From: Serum periostin does not reflect type 2-driven inflammation in COPD
ICS naive COPD | Healthy smoker | Healthy never-smoker | |
|---|---|---|---|
(n = 70) | (n = 22) | (n = 23) | |
Univariate regression | B exp (95% CI) | B exp (95% CI) | B exp (95% CI) |
Sex, male (%) | 4.7 (0.6–36.9) | 0.2 (0.004–11.4) | 1.9 (0.1–29.7) |
Smokers (%) | 0.4 (0.1–2.0) | NA | NA |
Linear regression | B (95% CI) | B (95% CI) | B (95% CI) |
Packyears (years) | 7.0 × 10− 5 (− 0.004–0.004) | NA | NA |
Age (years) | 0.01 (− 0.003–0.2) | 0.02 (0.01–0.03) * | 0.01 (− 0.01–0.03) |
BMI, (kg/m2) | 0.2 (− 0.1–0.1) | −0.1 (− 0.3–0.1) | 0.04 (− 0.1–0.2) |
% predicted FEV1 post-bronchodilator | −0.03 (− 0.01–0.01) | 0.01 (0.04–0.02) * | 0.01 (− 0.01–0.02) |
FEV1/IVC ratio (%) | 0.01 (− 0.004–0.01) | 0.0 (− 0.02–0.02) | 0.013 (− 0.02–0.04) |
RV/TLC ratio (%) | 0.003 (− 0.01–0.01) | 0.02 (− 0.02–0.1) | 0.02 (− 0.01–0.04) |
Fractional exhaled Nitric Oxide (ppb) | 0.001 (− 0.01–0.01) | NA | NA |
Total IgE (IU/L) | 4.2 × 10− 5 (0.0–0.0) | NA | NA |
PC20 methacholin threshold (mg/ml) # | 0.1 (− 0.03–0.1) | NA | NA |
Blood eosinophils (%) # | 0.1 (− 0.03–0.1) | − 0.07 (− 0.2–0.1) | 0.03 (− 0.2–0.2) |
Blood basophils (%) # | 0.04 (− 0.04–0.1) | −0.1 (− 0.2–0.1) | 0.1 (− 0.1–0.2) |
Blood neutrophils (%) | −0.001 (− 0.01–0.01) | − 0.004 (− 0.02–0.01) | −0.02 (− 0.04–0.01) |
Blood monocytes (%) | 0.03 (− 0.01–0.1) | 0.01 (− 0.1–0.1) | 0.02 (− 0.08–0.1) |
Blood lymphocytes (%) | −0.003 (− 0.01–0.01) | 0.01 (− 0.01–0.02) | 0.02 (− 0.01–0.04) |
Sputum eosinophils (%) | − 0.01 (− 0.1–0.04) | −0.01 (− 0.2–0.1) | 0.1 (− 0.1–0.2) |
Sputum neutrophils (%) | −7.7 × 10− 6 (− 0.01–0.01) | 0.002 (− 0.006–0.01) | −0.004 (− 0.01–0.01) |
Sputum macrophages (%) | −0.001 (− 0.01–0.01) | −0.002 (− 0.01–0.01) | 0.001 (− 0.01–0.01) |
Sputum lymphocytes (%) | 0.1 (− 0.01–0.1) | 0.108 (− 0.2–0.4) | 0.3 (0.1–0.5) * |
Biopsy eosinophils (count/0.1mm2) | −0.001 (− 0.003–0.002) | −0.03 (− 0.1–0.06) | 0.01 (− 0.03–0.04) |
Biopsy neutrophils (count/0.1mm2) # | 0.02 (− 0.03–0.08) | −0.002 (− 0.07–0.07) | −0.08 (− 0.2–0.04) |
Biopsy macrophages (count/0.1mm2) # | 0.045 (− 0.03–0.1) | −0.03 (− 0.1–0.1) | 0.03 (− 0.1–0.1) |
Biopsy lymphocytes (count/0.1mm2) | 0.000 (− 0.001–0.001) | −0.01 (− 0.01–0.002) | −0.02 (− 0.1–0.1) |
Biopsy elastic fibers area (%) | 0.002 (− 0.01–0.01) | NA | NA |
Biopsy elastic fibers density (gray value) | 0.002 (− 0.01–0.02) | NA | NA |
Biopsy versican area (%) | −0.001 (− 0.01–0.01) | NA | NA |
Biopsy versican density (gray value) | −0.01 (− 0.03–0.01) | NA | NA |
Biopsy decorin area (%) | − 8.15 × 10− 6 (< 0.001 – < 0.001) | NA | NA |
Biopsy decorin density (gray value) | −0.003 (− 0.1–0.045) | NA | NA |
Biopsy collagen I area (%) | −0.003 (− 0.01–0.01) | NA | NA |
Biopsy collagen I density (gray value) | 0.003 (− 0.02–0.03) | NA | NA |
Biopsy collagen III area (%) | −0.004 (− 0.01–0.03) | NA | NA |
Biopsy collagen III density (gray value) | −0.01 (− 0.02–0.01) | NA | NA |
Biopsy mean number of ki-67 pos. Cells (count/0.1mm2) | 0.001 (− 0.001–0.003) | NA | NA |
Biopsy PAS pos. Area epithelium (%) | 0.000 (− 0.01–0.01) | NA | NA |
Biopsy EGFR pos. Epithelium area (%) | 0.002 (− 0.01–0.01) | NA | NA |
Biopsy EGFR pos. Epithelium density (gray value) | 5.8 × 10− 6 (< 0.001 – < 0.001) | NA | NA |